Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discounts will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Compass Therapeutics has raised a total of $132 million in its first formal round of financing. The Cambridge, Mass.-based biotech firm was formed in 2014 to capitalize on a bispecific antibody screening platform that allows it to probe the activity of combinations of immune cells. It also boasts a discovery platform that swiftly yields therapeutics—either monoclonal or bispecific antibodies. Compass has more than 70 employees and expects to begin clinical studies of its most advanced drug candidate, an antibody against an undisclosed immuno-oncology target, in the first half of 2019.
This article has been sent to the following recipient: